Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 NUHpXXhjTnWwY4Tpc44hSXO|YYm= MnS1NE4yNTNyIN88US=> NGC2VWU1QCCq Ml;LbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> M2f3WlI3PTF|MUey
H460 MYnGeY5kfGmxbjDBd5NigQ>? NEW3SIwxNjFvM{Cg{txO MoHXOFghcA>? MWLpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MWWyOlUyOzF5Mh?=
HKESC-2 MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf3NlDDqM7:TR?= MoHGOFjDqGkEoB?= NIq1TWN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? NGm3dVEzPjR5NE[5Ny=>
CaES-17 M1LDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn33NlDDqM7:TR?= MXe0POKhcMLi MVnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> NWXJVGFJOjZ2N{S2PVM>
HKESC-2 M3PvXmFxd3C2b4Ppd{BCe3OjeR?= NGKxWHczOMLizszN M{PSPFQ5yqCqwrC= NEfMN|Jz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NHfEPY8zPjR5NE[5Ny=>
CaES-17 NHj2R5FCeG:ydH;zbZMhSXO|YYm= NWDCWHZXOjEEoN88US=> M17HRVQ5yqCqwrC= MV\y[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz Mk\4NlY1PzR4OUO=
A549 M37RbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW2[5k2NTF4MDFOwG0> NFHWeo81QMLiaNMg MnXzSG1UVw>? MoPkTWM2OD1zNkOuOEDPxE1? NX62fXlKOjZ2NkS2OFM>
HCC827 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7EWWxDPS1zNkCg{txO NGjpW5c1QMLiaNMg NYr4VodKTE2VTx?= MUfJR|UxRTZ7LkKg{txO M3XSfVI3PDZ2NkSz
A549 M3KxV2Fxd3C2b4Ppd{BCe3OjeR?= NUnreJBnQDBiwsXN MWG0POKhcMLi MWnEUXNQ MkHKbY5lfWOnczDhdI9xfG:|aYO= NUnYZ|U1OjZ2NkS2OFM>
HCC827 M2LnZ2Fxd3C2b4Ppd{BCe3OjeR?= MnqxPFAhyrWP MY[0POKhcMLi Mn3FSG1UVw>? MVjpcoR2[2W|IHHwc5B1d3Orcx?= M13qTVI3PDZ2NkSz
SGC-7901/DDP M4XocGZ2dmO2aX;uJGF{e2G7 M3XDN|ExyqEEtV2= MlnuNlQhcA>? MmjFbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> MWSyOlQxPzZ3Mx?=
SGC-7901  M{jJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPtNlTDqGkEoB?= MkPITWM2OD1zMUWuNFgh|ryP M32wclI3PDB5NkWz
SGC-7901/DDP MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzINlTDqGkEoB?= M{PCT2lEPTB;M{WuOFUh|ryP NF:wTFMzPjRyN{[1Ny=>
SGC-7901/DDP NXXpfVhUSXCxcITvd4l{KEG|c3H5 NVTz[YJbOTEEoNM1US=> NWi3SmltOjRiaB?= NGTmOHdqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv MWWyOlQxPzZ3Mx?=
SGC-7901/DDP NUC2V|B2TnWwY4Tpc44hSXO|YYm= NIm0NGQyOMLiwsXN NGTUbVkzPCCq NFvze3BqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= NH2xXnUzPjRyN{[1Ny=>
SGC-7901/DDP MlzsSpVv[3Srb36gRZN{[Xl? NFv0V4YyOMLiwsXN NXrNNox[OjRiaB?= MY\jZZV{\XNiYTDtZZJs\WRiZHXjdoVie2ViaX6geIhmKGyndnXsJI9nKEKlbD2yJJBzd3SnaX6= NFjKWlMzPjRyN{[1Ny=>
H357 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXVc4U4NjVxMUCg{txO MXi0PEBp NX3Jc3h{TE2VTx?= NIjyPIlqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5 MWmyOlAxQTh5NB?=
TAF NV6zRnlQTnWwY4Tpc44hSXO|YYm= NVfRZm9yOTEEoNM1US=> NYDIW|lYPyCm M{DYb4Fn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW| Ml\LNlU6QDdzMke=
TAF M4HWWmZ2dmO2aX;uJGF{e2G7 NUHnVoNIOTEEoNM1US=> M3S4WlMxNTF{MDDtbY4> NGXj[FJxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> M1\BUFI2QTh5MUK3
TAF MXrGeY5kfGmxbjDBd5NigQ>? M3\OXVExyqEEtV2= MomyOFghcA>? MWXpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MVeyOVk5PzF{Nx?=
PANC-1 M1vsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjpW|gzOC94MD:xNFAh|ryP NXjhOVlyOjRxNEivO|IhcA>? MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXXBeFhIOjV7N{OwOlI>
PANC-1 NFfpeFRHfW6ldHnvckBCe3OjeR?= MUeyNE83OC9zMECg{txO MV:yOEBp NV\IUGR7[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NVi2fWFiOjV7N{OwOlI>
HeLa  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm3NlDDqM7:TdMg Ml2wNlTDqGh? NXjTU|VV\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MW[yOVc4ODR{Mx?=
SACC-83 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6yNOKh|ryPwrC= MWKyOOKhcA>? NVXrVnJZ\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NHuzVXUzPTd5MESyNy=>
HeLa  M3rqXGFxd3C2b4Ppd{BCe3OjeR?= M3zLT|IxyqEQvF5CpC=> NVXncZZ3OjUEoHi= NHHXcGlmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ M3;zUFI2PzdyNEKz
SACC-83 M2HDT2Fxd3C2b4Ppd{BCe3OjeR?= NH;UfoczOMLizszNxsA> NYLNUnJwOjUEoHi= Ml73[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> NYTubFRIOjV5N{C0NlM>
HeLa  NVj6NYlMTnWwY4Tpc44hSXO|YYm= NInVRWwzOC92MD:4NEDPxE1? MUWyOOKhcA>? M3e3N5VxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV MU[yOVc4ODR{Mx?=
SACC-83 MUXGeY5kfGmxbjDBd5NigQ>? MnzaNlAwPDBxOECg{txO M1P5NFI1yqCq MV;1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NFXMUGkzPTd5MESyNy=>
HLCZ01 NHrKb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HQSVDjiJN4MNMgxtVO M{SwTFQ5KGh? MWXEUXNQ NV7ZelYycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlLNNlU4OjR6OUm=
HLCZ01 MnLWSpVv[3Srb36gRZN{[Xl? M3LoTVQxyqEQvF2= MViyOEBp NU\TWItpTE2VTx?= NYHvfm9ZcW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? Mm\5NlU4OjR6OUm=
HLCZ01 M2HJTmFxd3C2b4Ppd{BCe3OjeR?= MorROFDDqM7:TR?= NGPPVVkzPCCq NW\i[nRXTE2VTx?= NVL2N2ZM\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z MVqyOVczPDh7OR?=
HLCZ01 MnqySpVv[3Srb36gRZN{[Xl? NXH4ZY1yPDEEoN88US=> NFrwWYkzPCCq M2\6XGROW09? NHLa[W1qdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> M4PNRVI2PzJ2OEm5
MGC803 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMVYxKM7:TR?= NYL4RYp2PzJiaB?= MWfJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= MYCyOVcxOTN5OB?=
SGC7901 NX3kb|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G2R|AuPjBizszN Moe3O|IhcA>? M4LDPGlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN NWT0SWhrOjV5MEGzO|g>
MGC803 MXHGeY5kfGmxbjDBd5NigQ>? MnnVOFDDqM7:TR?= M2\POlgwOTZxMkSgbC=> M4rKNZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> Ml\5NlU4ODF|N{i=
SGC7901 NVn3RZJYTnWwY4Tpc44hSXO|YYm= NYDHW|g3PDEEoN88US=> MX[4M|E3NzJ2IHi= M3XuSpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NXjwTJE5OjV5MEGzO|g>
MCF-7  M4Tyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[xM|ExKM7:TR?= MY[3NkBp M2nhZWROW09? M1TPXoVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MoryNlU3Pjd3MUC=
MDA-MB-231  M1nEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnJc|FqOS9zMDFOwG0> M{jWfFczKGh? M4\sdmROW09? NXzM[odv\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NEPoUoszPTZ4N{WxNC=>
MDA-MB-231 NFPiTIVHfW6ldHnvckBCe3OjeR?= NHOydG8xNTRyINM1US=> NIPwT3Y1NTJ2IHi= MYTpcoNz\WG|ZYOgR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NEXlToYzPTV6N{OyPS=>
MCF-7 M1nTUmZ2dmO2aX;uJGF{e2G7 MWSwMVQxKML3TR?= NFzGVJY1NTJ2IHi= M33qd4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NHv3U|MzPTV6N{OyPS=>
MCF7-MX  MX\GeY5kfGmxbjDBd5NigQ>? MWWwMVQxKML3TR?= NF75R4o1NTJ2IHi= MkC0[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MY[yOVU5PzN{OR?=
MDA-MB-231 NFGwRYtHfW6ldHnvckBCe3OjeR?= M3zvO|AuPDBiwsXN MWq0MVI1KGh? NYPpd2RLe3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg M3H3SFI2PTh5M{K5
A2780 MnPQSpVv[3Srb36gRZN{[Xl? MmLGOU8yOC9zNTFOwG0> MWG0PEBp M2\6doRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3jVZlI2PDJ2OEm4
SKOV3  NHPieHBHfW6ldHnvckBCe3OjeR?= NXewZ4NjPS9zMD:xOUDPxE1? M3zsZlQ5KGh? MYDk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkiyNlU1OjR6OUi=
A2780 MXjGeY5kfGmxbjDBd5NigQ>? MUe1M|ExNzF3IN88US=> NWqzOHk1PDhiaB?= MXnlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv NH\p[ZUzPTR{NEi5PC=>
SKOV3  NH61dnFHfW6ldHnvckBCe3OjeR?= MWO1M|ExNzF3IN88US=> NG\2foc1QCCq MYnlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv MXWyOVQzPDh7OB?=
A2780 MUDGeY5kfGmxbjDBd5NigQ>? MljLOU8yOC9zNTFOwG0> NY\JOFFEPDhiaB?= M2jQdIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= MV:yOVQzPDh7OB?=
SKOV3  MY\GeY5kfGmxbjDBd5NigQ>? NU\BcYdyPS9zMD:xOUDPxE1? M1nwZ|Q5KGh? NV3rd4p5\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NHq4cYIzPTR{NEi5PC=>
A2780 MkjESpVv[3Srb36gRZN{[Xl? Ml;OOU8yOC9zNTFOwG0> MVWxJIg> MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGLZfW0zPTR{NEi5PC=>
SKOV3  Ml\FSpVv[3Srb36gRZN{[Xl? M1XkT|UwOTBxMUWg{txO NYPycIFrOSCq MYTpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NInT[HYzPTR{NEi5PC=>
HCT-15 M4GwT2Z2dmO2aX;uJGF{e2G7 MmPMNVAuPTBizszN M4XySFYuOzZiaB?= NFPLclFqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NH[5dpIzPTJzOECyPC=>
HT-29  NGT2XphHfW6ldHnvckBCe3OjeR?= NEnv[VEyOC13MDFOwG0> M1XLU|YuOzZiaB?= NXHOd4NmcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MXyyOVIyQDB{OB?=
HSC3  NXnJZZpES2WubDDWbYFjcWyrdImgRZN{[Xl? MmXiNQKBmzRyIN88US=> MXe0PEBp MUTJR|UxRTJ3LkZCtVEvPzhyIN88US=> MWmyOVE6QDd6OR?=
HSC3  MXXBdI9xfG:|aYOgRZN{[Xl? MXWyOUDPxE1? MV20PEBp NYfJO4x4cW6mdXPld{BieG:ydH;zbZM> NIfQOHQzPTF7OEe4PS=>
HSC3  NHfhTVNHfW6ldHnvckBCe3OjeR?= NYD5bXlkOjVizszN NGHXPGc1QCCq M4X6TYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? M1;LXVI2OTl6N{i5
HSC3  NUT1VGlFTnWwY4Tpc44hSXO|YYm= NIPnPIczPSEQvF2= NV3wSJk2PDhiaB?= NXrRb4xYcW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NVP2emRuOjVzOUi3PFk>
HSC3  NVTUPJlRTnWwY4Tpc44hSXO|YYm= MXWyOUDPxE1? M17tbFczKGh? NGXjb25l\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> MmjYNlUyQTh5OEm=
201T  NGLUfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqwO|IhcA>? MUfEUXNQ NFvn[mhKSzVyPUS4MlYhyrWP MVuyOVA2Pzl2MR?=
273T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fhcFczKGh? Mn32SG1UVw>? NUnIe2U3UUN3ME24NE42KML3TR?= NHrQU44zPTB3N{m0NS=>
Hep-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hN|AwPTBxMUCwJO69VQ>? NEfIbGYyOi9{ND:zOk81QCCq MkXJSG1UVw>? NWHkcJltcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NYnFOnU5OjR7OUi1OlQ>
Hep-2 M1u2NmFxd3C2b4Ppd{BCe3OjeR?= MXq1NEDPxE1? NUm3dZdMOC12ODDo MVnEUXNQ NULJZVJDcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NGnNeGYzPDl7OEW2OC=>
Hep-2 Mlz1SpVv[3Srb36gRZN{[Xl? M2mweVUxKM7:TR?= NUWzXpZ{OC12ODDo MULEUXNQ NHTUfm5z\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= MVqyOFk6QDV4NB?=
Hep-2 MmK3SpVv[3Srb36gRZN{[Xl? NXLDUHJFPTBizszN M2nKOVAuPDhiaB?= MWfEUXNQ MkK4[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> MVWyOFk6QDV4NB?=
SGC-7901 M{jHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP0NVAwPTBxMUCwJO69VQ>? MkH1NlQwPDhxN{KgbC=> MoPTSG1UVw>? MmCxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoLkNlQ6QTJ7NUi=
MKN-45 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13MXVExNzVyL{GwNEDPxE1? M3fPU|I1NzR6L{eyJIg> MmTKSG1UVw>? MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NE\iNZgzPDl7Mkm1PC=>
SGC-7901 NYfYUXZrTnWwY4Tpc44hSXO|YYm= NUXTR4hWOTBxNUCvNVAxKM7:TR?= MUm0PEBp MnHYSG1UVw>? M{XBeIRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mk\WNlQ6QTJ7NUi=
MKN-45 M{TPSWZ2dmO2aX;uJGF{e2G7 NV7MdGFuOTBxNUCvNVAxKM7:TR?= M2KwR|Q5KGh? NGHofG9FVVOR M4K0cYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1;pSVI1QTl{OUW4
C666-1 NIO1PFNEgXSxdH;4bYNqfHliQYPzZZk> Mk\ONlAuQDBizszN MUWyOEBp MVTk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NY\wN2t7OjR6NUS4N|g>
CNE-1 NXfPS4tyS3m2b4TvfIlkcXS7IFHzd4F6 NHHJOJAzOC16MDFOwG0> MX2yOEBp MUnk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg M1jXeVI1QDV2OEO4
CNE-2 NFzidopEgXSxdH;4bYNqfHliQYPzZZk> MoK0NlAuQDBizszN MnTDNlQhcA>? M4\MT4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NX24SY8xOjR6NUS4N|g>
C666-1 MYrDfZRwfG:6aXPpeJkhSXO|YYm= MnXHOlAh|ryP MkDLO{Bl MnWx[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= MmjxNlQ5PTR6M{i=
CNE-1 NFLQV3dEgXSxdH;4bYNqfHliQYPzZZk> NGPR[ZY3OCEQvF2= M3r2blch\A>? MmXp[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= NHr0[4MzPDh3NEizPC=>
SNU-1041 M3fIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXHUY56OC12MDFOwG0> Mn3JOFghcA>? M{TSTIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MX:yOFY6OjdyMx?=
SNU-1041 M2XGTWZ2dmO2aX;uJGF{e2G7 M17pUlIxNzNyIN88US=> NY\CU3doPCCq Mki5bY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> NXTJOW9UOjR4OUK3NFM>
SNU-1041 NF7kbVBHfW6ldHnvckBCe3OjeR?= NYnQNI5YOC12MDFOwG0> MVO0JIg> NV3JTFNqfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= M3nCO|I1Pjl{N{Cz
SGC-7901 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXRWGx1PTBvMUK1JO69VQ>? NEfXNIszPC92OD:3NkBp NIL6No9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3TxNFI1Pjd4M{m0
SGC-7901 NXHiO2txSXCxcITvd4l{KEG|c3H5 M4jCR|ExOCEQvF2= NVTSZm1DPzJiaB?= NEKze5ZqdmS3Y3XzJIFxd3C2b4Ppdy=> M1u4S|I1Pjd4M{m0
SGC-7901 MYnGeY5kfGmxbjDBd5NigQ>? MVm3OU8yODBxMUK1JO69VQ>? MXSyOE81QC95MjDo NVG2XpAycW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> M3W0c|I1Pjd4M{m0
LMeC  M{XiemZ2dmO2aX;uJGF{e2G7 M4mzelIxNzVyIN88US=> NHfXdIY1QCCq M{P6W4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw M{fHXVI1PjV4N{S2
CMeC-1 NXvRT4NzS2WubDDWbYFjcWyrdImgRZN{[Xl? MWCyNE82OCEQvF2= MmTvOFghcA>? MljybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlTjNlQ3PTZ5NE[=
LMeC MmPGR4VtdCCYaXHibYxqfHliQYPzZZk> MonLNlAwPTBizszN NHHrRmE1QCCq MnnnbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4fSS|I1PjV4N{S2
CMeC-1 MWHGeY5kfGmxbjDBd5NigQ>? NWP6Ooo1OjBxNUCg{txO Mly4OFghcA>? M4D6e4lv\HWlZYOgS|EuWyCjcoLld5Q> MkjtNlQ3PTZ5NE[=
LMeC Mm\0SpVv[3Srb36gRZN{[Xl? M{Xk[|IxNzVyIN88US=> NGrvfGQ1QCCq Mkj0bY5lfWOnczDHNU1UKGG{cnXzeC=> MlXZNlQ3PTZ5NE[=
CMeC-1 NXvFTXU6TnWwY4Tpc44hSXO|YYm= M1nvfFIxNzVyIN88US=> M4G3WFQ5KGh? NY[xVI9s\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn3HNlQ3PTZ5NE[=
LMeC NH63UpFHfW6ldHnvckBCe3OjeR?= M4PRU|IxNzVyIN88US=> NF\CTIM1QCCq MVPk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGXwNHYzPDZ3Nke0Oi=>
CMeC-1 NUjTUlJ7TnWwY4Tpc44hSXO|YYm= NHe3Z2IzOC93MDFOwG0> NX\4eYI2PDhiaB?= M{Hx[Ilv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M{LpVVI1PjV4N{S2
LMeC M1\ER2Z2dmO2aX;uJGF{e2G7 NYfBVZZTOjBxNUCg{txO MWK0PEBp MX;pcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NYm0U3NFOjR4NU[3OFY>
OVCAR-3 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIDMbYQyOCEEtV2= Mlr0NUBp MVvlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NVLMRYoxOjR3MkCyNlc>
OVCAR-3 NHrBe5FCeG:ydH;zbZMhSXO|YYm= M{jse|ExKML3TR?= MmHJNUBp M3\kdZBzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>? NFK0fo8zPDV{MEKyOy=>
OVCAR-3 NGewfohHfW6ldHnvckBCe3OjeR?= NFT6fWYyOCEEtV2= NUSzcIs4OSCq MV;lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?= NEHnOVkzPDV{MEKyOy=>
OVCAR-3 MUjGeY5kfGmxbjDBd5NigQ>? NUPXc|ZqOTBiwsXN NHzPfJUyKGh? NV\lRmFR\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt NX7vdWdOOjR3MkCyNlc>
OVCAR-3 NVm4[mNqTnWwY4Tpc44hSXO|YYm= M{PJO|ExKML3TR?= NEfiZ4oyKGh? MlPqbY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NVjo[JZFOjR3MkCyNlc>
CF33 NHvxUJhHfW6ldHnvckBCe3OjeR?= Mny1NVAxKM7:TR?= MoG0NlQhcA>? NHjHO5dqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= Mn63NlQ2ODN5OEK=
CF33 NHfaeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LoU|ExNTFyMDFOwG0> MWSwMVQh\A>? NIXvPYlqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWri[mxyOjR3MEO3PFI>
CF33 MkTOSpVv[3Srb36gRZN{[Xl? Ml;DNVAuOTByIN88US=> MXS0MVI1KGh? MXvk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> Mnf1NlQ2ODN5OEK=
LNCaP MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PlNlIwPS9zMDFOwG0> NEfnTXY6PiCq NIXzVZNqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu NXv2ZWVEOjR{OU[5O|g>
LNCaP MVvBdI9xfG:|aYOgRZN{[Xl? NWPwZ3E4Oi93L{GwJO69VQ>? MmfiPVYhcA>? NF7tOoJqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NWDFb|YzOjR{OU[5O|g>
PC-3  MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmwMVUxKM7:TR?= M1q1b|Q56oDLaB?= NHXySm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mn7sNlQyOjd6OEK=
PC-3  MkOwR4VtdCCYaXHibYxqfHliQYPzZZk> NW\xcplxOC1zMECg{txO MmG5O|IhcA>? MlfP[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MXGyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 3年-20℃
2年-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

文献中の引用 (6)

Frequently Asked Questions

  • Question 1
    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

    Answer: For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ